Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 672 entries
View as:

Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

Phase: N/A Priority: Normal
NCT ID: NCT00061425 Org: User:
Start: 08/31/00 End: - Due: -

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01956812 Org: User:
Start: 12/31/13 End: 11/30/16 Due: 11/30/17

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Phase: N/A Priority: Normal
NCT ID: NCT02671500 Org: User:
Start: 04/19/16 End: 03/27/18 Due: 03/27/19

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00353574 Org: User:
Start: 09/30/06 End: 04/30/10 Due: 04/30/11

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT02854605 Org: User:
Start: 10/26/16 End: 01/09/18 Due: 01/09/19

Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.

Phase: N/A Priority: Normal
NCT ID: NCT00270556 Org: User:
Start: 01/31/03 End: 10/31/04 Due: 10/31/05

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02868242 Org: User:
Start: 08/28/16 End: 02/03/19 Due: 02/03/20

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Phase: N/A Priority: Normal
NCT ID: NCT02842086 Org: User:
Start: 09/02/16 End: 09/30/27 Due: 09/30/28

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02226549 Org: User:
Start: 07/31/14 End: 02/28/15 Due: 02/28/16

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT01309243 Org: User:
Start: 02/28/11 End: 02/28/14 Due: 02/28/15

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01980875 Org: User:
Start: 04/21/15 End: 05/13/16 Due: 05/13/17

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Phase: N/A Priority: Normal
NCT ID: NCT00836914 Org: User:
Start: 02/28/09 End: 03/31/09 Due: 03/31/10

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Phase: N/A Priority: Normal
NCT ID: NCT01252940 Org: User:
Start: 11/30/10 End: 10/31/14 Due: 10/31/15

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01591668 Org: User:
Start: 03/31/12 End: 12/31/12 Due: 12/31/13

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Phase: N/A Priority: Normal
NCT ID: NCT03631732 Org: User:
Start: 08/28/18 End: 08/19/20 Due: 08/19/21

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT01108510 Org: User:
Start: 04/30/10 End: 04/30/15 Due: 04/30/16

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02365532 Org: User:
Start: 02/28/15 End: 05/31/15 Due: 05/31/16

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

Phase: N/A Priority: Normal
NCT ID: NCT01651403 Org: User:
Start: 12/06/12 End: 07/31/27 Due: 07/31/28

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01796470 Org: User:
Start: 06/20/13 End: 12/22/16 Due: 12/22/17

Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00380068 Org: User:
Start: 08/31/06 End: 05/31/09 Due: 05/31/10

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00041652 Org: User:
Start: 02/29/00 End: 06/30/03 Due: 06/30/04

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Phase: N/A Priority: Normal
NCT ID: NCT00528957 Org: User:
Start: 12/28/06 End: 08/16/17 Due: 08/16/18

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01188772 Org: User:
Start: 08/31/10 End: 05/31/12 Due: 05/31/13

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

Phase: N/A Priority: Normal
NCT ID: NCT01416402 Org: User:
Start: 08/31/11 End: 10/31/11 Due: 10/31/12

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02639338 Org: User:
Start: 12/23/15 End: 01/02/17 Due: 01/02/18